Outcome of Board Meeting held on Tuesday 11th August, 2026 pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

BIOFIL CHEMICALS AND PHARMACEUTICALS LIMITED CIN: L24233MP1985PLC002709 Registered Office: B/12-B, Industrial Estate, Pologround, Indore-452015 (M.P.) Tel. 0731-2426700; Email id- bcplcompliance@gmail.com; Website- www.biofilgroup.net; Fax: 0731-2426700 Date: 11‘: August, 2026 To, To, The Secretary (DCS/Compliance), The Secretary (Listing/Compliance), Corporate Relationship Department, Corporate Relationship Department, BSE Limited National Stock Exchange of India Limited, Phiroze Jeejeebhoy Towers, Exchange Plaza, C-1, Block G, Bandra Kurla Dalal Street, Mumbai-400001 Complex, Mumbai - 400051 Subject: Outcome of Board Meeting held on Tuesday 11‘ August, 2026 pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Reference: Biofil Chemicals & Pharmaceuticals Limited (BSE Scrip Code: 524396; NSE Symbol: BIOFILCHEM; ISIN: INE829A01014) Dear Sir/Madam, With reference to the above captioned subject and in pursuant to the Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that Board of Directors of the Company in their meeting (Serial No. 02/2026-27) held on today i.e, Tuesday, 11 Day of August, 2026, has inter alia, considered and approved the following businesses: 1. Un-Audited Financial Results of the Company for the quarter ended on 30* June, 2026 along with limited Review Report thereon. (Copy of financial results enclosed herewith). 2. Continuation of directorship of Mr. Ashok Kumar Ramawat (DIN: 08818263) as a Non-Executive Independent Director of the Company, upon attaining the age of 75 (seventy-five) years, based on recommendations of Nomination and Remuneration Committee. 3. Approval of Board’s Report on the Operation of the Company along with required annexure and Corporate Governance Report & Management Discussion and Analysis Report for the year ended March 31, 2026. 4. Convening of 41s Annual General Meeting (AGM) on Wednesday, 23™ day of September, 2026 at 03.00 P.M. (IST) through Video Conferencing (VC) or Other Audio-Visual Means (OAVM). 5. Other routine businesses with the permission of Chair. Further, Continuous Disclosure as required pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD- PoD2/1/3762/2026 dated 30" January, 2026 as amended from time to time are being submitted separately in pdf and xbrl form with in prescribed time limit. Furthermore, copy of Un-Audited Financial Results of the Company shall also be submitted in integrated filing financials XBRL within prescribed time limit from the conclusion of Board Meeting. The aforesaid Un-Audited Financial Results of the Company shall also be uploaded on the Company's website ie. www.biofilgroup.net and on the website of the Stock Exchanges i.e., at www.bseindia.com and www.nseindia.com. Further, publication containing a Quick Response code and the details of the webpage where complete financial results of the Company are available will be published in Hindi and English Newspapers with in prescribed time limit. The Meeting of the Board of Directors commenced at 04:30 P.M. and concluded at 05:30 P.M. The above information will also be available on the website of the Company at www. biofilgroup.net. You are requested to please take on record the same. Thanking you. Yours Faithfully, FOR BIOFIL CHEMICALS AND PHARMACEUTICALS LIMITED APOORV JAIN COMPANY SECRETARY & COMPLIANCE OFFICER M. NO. A71739 Cx MAHESHWARI & GUPTA CHARTERED ACCOUNTANTS INDIA Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Standalone Financial Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended The Board of Directors Biofil Chemicals and Pharmaceuticals Limited Indore (M.P.) We have reviewed the accompanying statement of unaudited Standalone Financial results (“the statement”) of Biofil Chemicals and Pharmaceuticals Limited (“the company”) for the quarter ended 30" June, 2026 and year to date from 01% April, 2026 to 30" June, 2026 attached herewith. The Statement has been prepared by the Company’s Management pursuant to requirement of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015 as amended (“the listing regulations”). This statement, which is the responsibility of the Company’s management and approved by the Board of Directors has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 (Ind AS 34) “Interim Financial Reporting” prescribed under Section 133 of the Companies Act, 2013 as amended, read with rule 3 of Companies (Indian Accounting Standards) Rules, 2015 (as amended), in compliance with Regulation 33 issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the statements based on our review. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by Independent Auditor of the Entity” issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures, A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would be 312-314, MANAS BHAWAN Extn., 11/2 R.N.T. Marg, Indore-452001(M.P.) Ph.: (0731) 4050760, E-mail: maheshwarigupta1753@gmail.com, camng92@gmail.com MAHESHWARI & GUPTA CHARTERED ACCOUNTANTS aware of all significant matters that might be identified in an audit. We have not performed an audit and accordingly, we do not express an audit opinion. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with recognition and measurement principles laid down in the aforesaid Indian Accounting Standard (Ind AS) and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement. For MAHESHWARI & GUPTA Place: Indore Date: 11/08/2026 UDIN: 26403346HUTRDG7531 312-314, MANAS BHAWAN Extn., 11/2 R.N.T. Marg, Indore-452001(M.P.) Ph.: (0731) 4050760, E-mail: maheshwarigupta1753@gmail.com, camng92@gmail.com ~ orn. BIOFIL CHEMICALS AND PHARMACEUTICALS LIMITED ] SOF TL CIN NO. L24233MP1985PLC002709 Wealth For He Regd Off: B/12-B, Industrial Estate, Pologround, Indore-452015 (M.P.) Email Id:bcplcompliance@gmail.com Phone No. 0731-2426700, Website: www.biofilgroup.net Amount in Lakhs except EPS) Statement of Unaudited Financial Results for the quarter ended 30th June 2026 tad Particulars Quarter Ended Previous Year Ended : June 30, 2026 June 30,2025 March 31, 2026 March 31, 2026 Un-Audited Un-Audited Audited Audited ]__|Revenue from Operation 1235.02 643.26 756.56 2839.52 Il |Other Income 6.26 283.20 10.85 308.23 Ill |T otal Income 1241.28 926.46 767.41 3147.75 IV_ |Expenses (a) Cost of materials consumed a= 948.18 117.14 179.84 738.32 (b) Purchases of stock-in-trade 311.58 974.06 195.43 1876.95 (c) Changes in inventories off inished goods, work-in- : progress and stock-in-trade (81.18) (497.91) 282.96 (19.19) (d) Employee benefits expense 19.36 21.04 22.00 7 [Showing first 8,000 characters — download PDF for full document]